



**NORRIS**  
**MEDICINES LIMITED**



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Regd. Office : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Telephone : (02646) 223462, 227530  
Fax : (02646) 250126  
E-mail : contact@norrispharma.com  
Website : www.norrispharma.com  
CIN : L24230GJ1990PLC086581

Date: 14<sup>th</sup> August, 2017

To,

The Manager  
Listing Department  
The Bombay Stock Exchange Ltd,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Code: 524414**

**Sub: Submission of Standalone Unaudited Financial Results in Compliance with Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

1. Standalone Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2017.
2. Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2017

Thanking you,


Yours faithfully,  
For **NORRIS MEDICIENS LIMITED**

  
**Vinay Rana**  
**(Company Secretary)**





**NORRIS**  
**MEDICINES LIMITED**



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Telephone : (02646) 223462, 227530  
 Fax : (02646) 250126  
 E-mail : contact@norrispharma.com  
 Website : www.norrispharma.com  
 CIN : L24230GJ1990PLC086581

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017**

Sr. No.	Particulars	(Rs. In Lacs)			
		Quarter ended			Year ended
		30-06-2017 (Unaudited)	31-03-2017 (Audited)	30-06-2016 (Unaudited)	31-03-2017 (Audited)
i	Revenue from Operations	350.86	436.98	417.89	2045.68
ii	Other Income	0.57	12.38	0.07	13.96
iii	<b>Total Revenue(i+ii)</b>	<b>351.43</b>	<b>449.36</b>	<b>417.96</b>	<b>2059.64</b>
iv	<b>Expenses</b>				
	(a) Cost of materials consumed	122.94	248.62	192.29	1052.05
	(b) Change in inventories of finished goods work in progress and stock-in-trade	46.23	-18.46	7.67	-11.97
	(c) Employee benefits expense	138.11	129.51	116.49	530.78
	(d) Finance cost	17.33	21.08	12.15	60.12
	(e) Depreciation and amortisation expense	16.15	21.10	14.50	64.60
	(f) Other Expense	101.41	142.90	97.48	482.36
	<b>Total Expenses (iv)</b>	<b>442.17</b>	<b>544.75</b>	<b>440.58</b>	<b>2177.94</b>
v	<b>Profit / (Loss) before exceptional and extraordinary itmes and tax (iii-iv)</b>	<b>-90.74</b>	<b>-95.39</b>	<b>-22.62</b>	<b>-118.30</b>
vi	Exceptional itmes	0.00	0.00	0.00	0.00
vii	<b>Profit / (Loss) before extraordinary itmes and tax (v-vi)</b>	<b>-90.74</b>	<b>-95.39</b>	<b>-22.62</b>	<b>-118.30</b>
viii.	Extraordinary items	0.00	0.00	0.00	0.00
ix	<b>Profit / (Loss) before tax (vii-viii)</b>	<b>-90.74</b>	<b>-95.39</b>	<b>-22.62</b>	<b>-118.30</b>
x	<b>Tax Expense</b>				
	(a) Current Tax	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	41.57	0.00	41.57
xi	<b>Profit / (Loss) after tax</b>	<b>-90.74</b>	<b>-53.82</b>	<b>-22.62</b>	<b>-76.73</b>
xii	<b>Basic and Diluted Earning per equity share</b>	<b>-0.91</b>	<b>-0.54</b>	<b>-0.23</b>	<b>-0.77</b>

**Notes:**

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.08.2017.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- The above Results, have been prepared in accordance with Ind AS notified under the companies (Indian Accounting Standards) Rules, 2015.

Reconciliation of Net Profit between Previous GAAP and Ind AS:

**Standalone Financial Results.**

Nature of Adjustment	Rs. In Lacs
	Quarter Ended 30.06.2016
Net Profit Under Previous GAAP	(22.62)
Actuarial gain / (Loss) on employees defined benefit funds recognised in Other Comprehensive Income (Net)	-
Net gain / (Loss) on financial assets at fair value through profit and Loss	-
Net Profit under per Ind As	(22.62)

- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable

For NORRIS MEDICINES LIMITED

Date : 14.08.2017  
 Place : Ahmedabad



Vimal D Shah  
 Managing Director

**Review Report to the Board of Directors**  
**Norris Medicines Limited**  
**Ankleshwar.**

We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 30<sup>th</sup> June, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH

Date : 14<sup>th</sup> August, 2017

232, Rangoli Complex,  
Station Road,  
Bharuch – 392 001  
Gujarat.

For, **MINU MODI & CO.**  
Chartered Accountants  
  
CA **MINU MODI**  
Proprietor  
M. No. 100289  
(Firm Reg. No. 119948W)